Bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. Several recent findings that there are activating mutations in the KIT and PDGFRA (platelet-derived growth factor receptor-α) genes of GISTs provide the rationale for using targeted therapies...

Full description

Bibliographic Details
Main Authors:	Kim, Hyo-Sin, Kim, Sung-Soo, Park, Sang-Gon
Format:	Online
Language:	English
Published:	The Korean Surgical Society 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996717/

id	pubmed-3996717
recordtype	oai_dc
spelling	pubmed-39967172014-04-29 Bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor Kim, Hyo-Sin Kim, Sung-Soo Park, Sang-Gon Case Report Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. Several recent findings that there are activating mutations in the KIT and PDGFRA (platelet-derived growth factor receptor-α) genes of GISTs provide the rationale for using targeted therapies such as imatinib or sunitinib. Sunitinib, an oral multitargeted receptor tyrosine kinase inhibitor that inhibits kinases such as KIT, PDGFR (platelet-derived growth factor recepter), and VEGFR (vascular endothelial growth factor receptor), was recently approved for the treatment of imatinib-refractory GIST. Sunitinib is generally well tolerated and has an acceptable toxicity profile; an adverse event such as bowel perforation is rare. We present a patient with imatinib-refractory GIST who was successfully treated using sunitinib, but developed bowel perforation. The mechanism involved in bowel perforation associated with sunitinib is unknown. However, we presume that in our patient, the dramatic reduction in disseminated peritoneal metastases and bowel invasion of recurrent GIST during sunitinib treatment might have resulted in the bowel perforation. The Korean Surgical Society 2014-04 2014-03-25 /pmc/articles/PMC3996717/ /pubmed/24783183 http://dx.doi.org/10.4174/astr.2014.86.4.220 Text en Copyright © 2014, the Korean Surgical Society http://creativecommons.org/licenses/by-nc/3.0/ Annals of Surgical Treatment and Research is an Open Access Journal. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Kim, Hyo-Sin Kim, Sung-Soo Park, Sang-Gon
spellingShingle	Kim, Hyo-Sin Kim, Sung-Soo Park, Sang-Gon Bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor
author_facet	Kim, Hyo-Sin Kim, Sung-Soo Park, Sang-Gon
author_sort	Kim, Hyo-Sin
title	Bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor
title_short	Bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor
title_full	Bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor
title_fullStr	Bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor
title_full_unstemmed	Bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor
title_sort	bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor
description	Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. Several recent findings that there are activating mutations in the KIT and PDGFRA (platelet-derived growth factor receptor-α) genes of GISTs provide the rationale for using targeted therapies such as imatinib or sunitinib. Sunitinib, an oral multitargeted receptor tyrosine kinase inhibitor that inhibits kinases such as KIT, PDGFR (platelet-derived growth factor recepter), and VEGFR (vascular endothelial growth factor receptor), was recently approved for the treatment of imatinib-refractory GIST. Sunitinib is generally well tolerated and has an acceptable toxicity profile; an adverse event such as bowel perforation is rare. We present a patient with imatinib-refractory GIST who was successfully treated using sunitinib, but developed bowel perforation. The mechanism involved in bowel perforation associated with sunitinib is unknown. However, we presume that in our patient, the dramatic reduction in disseminated peritoneal metastases and bowel invasion of recurrent GIST during sunitinib treatment might have resulted in the bowel perforation.
publisher	The Korean Surgical Society
publishDate	2014
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996717/
_version_	1612081347353903104

Bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor

Similar Items